Source comparison
CJC-1295 with DAC vs Modified GRF 1-29: Dosing Protocols
CJC-1295 with DAC 6–8 days 200–1000mcg Once or twice weekly 4–10 doses Sustained GH elevation via albumin binding; non-pulsatile release Modified GRF 1-29 (CJC-1295 no DAC) ~30 minutes 100–200mcg 1–3 times daily 13–20 doses (per-injection basis) Pulsatile GH r
This comparison does not assign a generated winner or score.
- CJC-1295 with DAC
- 6–8 days
- 200–1000mcg
- Once or twice weekly
- 4–10 doses
- Sustained GH elevation via albumin binding; non-pulsatile release
- Modified GRF 1-29 (CJC-1295 no DAC)
- ~30 minutes
- 100–200mcg
- 1–3 times daily
- 13–20 doses (per-injection basis)
- Pulsatile GH release mimicking natural secretion; rapid clearance
- CJC1295 Ipamorelin 5MG 5MG blend
- Variable (dual action)
- 200–300mcg combined
- Once daily to twice daily
- 16–25 doses
- Synergistic GH release. CJC sustains, ipamorelin amplifies pulse
- CJC-1295 with DAC creates continuous growth hormone elevation by preventing peptide clearance. The DAC modification forms a stable complex with serum albumin that keeps circulating peptide levels elevated for up to eight days post-injection. This mechanism suits protocols targeting sustained anabolic effects or metabolic enhancement where stable GH levels matter more than preserving natural pulse rhythm. Modified GRF 1-29 mimics endogenous growth hormone-releasing hormone (GHRH) by stimulating pituitary somatotrophs in short, intense pulses. Its 30-minute half-life means GH elevation peaks within 15–30 minutes post-injection and returns to baseline within 2–3 hours, preserving the body's natural feedback loops that regulate GH secretion.
- Protocol design for CJC-1295 with DAC typically doses 200–500mcg once weekly or 500–1000mcg twice weekly depending on research objectives. A 2mg vial at 500mcg per dose yields four total injections across two weeks of a twice-weekly protocol. Modified GRF 1-29 protocols dose 100–200mcg per injection 1–3 times daily, often stacked with a growth hormone secretagogue like ipamorelin or GHRP-2 to amplify pulsatile release. A researcher administering 100mcg three times daily uses 300mcg total per day, consuming a 2mg vial in approximately 6.67 days. Planning inventory around weekly vial turnover prevents mid-protocol stock gaps.
- Blended formulations like CJC1295 Ipamorelin 5MG 5MG combine modified GRF 1-29 with a GHRP in a single vial to simplify dosing logistics. These blends typically dose 200–300mcg combined peptide mass per injection once or twice daily. A 5mg blend vial at 250mcg per dose yields twenty injections. Splitting the vial between morning and pre-sleep administrations extends it across ten days of a twice-daily protocol. Our team finds pre-mixed blends reduce reconstitution complexity and measurement error for researchers running multi-peptide stacks.